FindTrial
Sign In

Comparison of intralesional 5-fluorouracil with MMR vaccine in warts

Comparative efficacy of intralesional 5-Fluorouracil and intralesional MMR vaccine in verruca vulgaris - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/12/060907
Enrollment
52
Registered
2023-12-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B079- Viral wart, unspecified

Interventions

Intervention1: 5-Fluorouracil: 26 patients will be given intralesional 5-Fluorouracil in all lesions at 2 weekly intervals for a total of 5 sessions Control Intervention1: MMR vaccine: 26 patients wil

Sponsors

Department of Dermatology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All consecutive patients having lesions of verruca vulgaris. 2. Patients between the ages of 14-60 years.

Exclusion criteria

Exclusion criteria: 1. Pregnant or females planning for pregnancy or lactating mothers. 2. Immunocompromised individuals including HIV-AIDS. 3. Patients with known hypersensitivity to MMR vaccine or components of the vaccine (e.g. neomycin, gelatin) or 5-FU. 4. Patients having any significant systemic illness. 5. Patients having taken any vaccine in the last 4 weeks.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of intralesional 5-FU and intralesional MMR vaccine therapy in verruca vulgarisTimepoint: 0, 2, 4, 6, 8, 12 weeks—

Secondary

MeasureTime frame
To assess the adverse effects of these therapiesTimepoint: 0, 2, 4, 6, 8, 12 weeks—

Countries

India

Contacts

Public ContactDr Jasleen Kaur

Government Medical College and Hospital, Chandigarh

jasleenksandhu21@gmail.com9646481249

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026